Search research articles
Contact Us
Filters
Showing results (211-220 of 227) with videos related to
Page
of 23
Sort By:
Journal of the National Cancer Institute
|
September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
Cancer
|
March 14, 2020
Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis
James R Broughman, David D Xiong, Benjamin J Moeller, et al.
Head & Neck
|
September 12, 2020
Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: Multi-institutional oral cavity collaboration study
Sara W Liu, Neil M Woody, Wei Wei, et al.
Oral Oncology
|
October 31, 2020
Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design
Christopher W Fleming, Matthew C Ward, Neil M Woody, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 19, 2025
Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer - Results from xxxxx
Christina L Runge, Jessica A Lyness, Maura L Gillison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
Sue S Yom, Pedro Torres-Saavedra, Jimmy J Caudell, et al.
Journal for Immunotherapy of Cancer
|
June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Danny Rischin, Michael R Migden, Annette M Lim, et al.
The Lancet. Oncology
|
October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Neil D Gross, David M Miller, Nikhil I Khushalani, et al.
Cancer Discovery
|
August 8, 2024
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Justin F Gainor, Manish R Patel, Jeffrey S Weber, et al.
The New England Journal of Medicine
|
September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neil D Gross, David M Miller, Nikhil I Khushalani, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 227) with videos related to
Sort By:
Page
of 23
Journal of the National Cancer Institute
|
September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
Cancer
|
March 14, 2020
Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis
James R Broughman, David D Xiong, Benjamin J Moeller, et al.
Head & Neck
|
September 12, 2020
Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: Multi-institutional oral cavity collaboration study
Sara W Liu, Neil M Woody, Wei Wei, et al.
Oral Oncology
|
October 31, 2020
Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design
Christopher W Fleming, Matthew C Ward, Neil M Woody, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 19, 2025
Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer - Results from xxxxx
Christina L Runge, Jessica A Lyness, Maura L Gillison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
Sue S Yom, Pedro Torres-Saavedra, Jimmy J Caudell, et al.
Journal for Immunotherapy of Cancer
|
June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Danny Rischin, Michael R Migden, Annette M Lim, et al.
The Lancet. Oncology
|
October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Neil D Gross, David M Miller, Nikhil I Khushalani, et al.
Cancer Discovery
|
August 8, 2024
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Justin F Gainor, Manish R Patel, Jeffrey S Weber, et al.
The New England Journal of Medicine
|
September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neil D Gross, David M Miller, Nikhil I Khushalani, et al.
Page
of 23